The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.
 
Kristina Fanucci
No Relationships to Disclose
 
Mary Josephine Paula Pilat
No Relationships to Disclose
 
Ritu Shah
No Relationships to Disclose
 
Scott Anthony Boerner
No Relationships to Disclose
 
Jing Li
No Relationships to Disclose
 
Diane E. Durecki
No Relationships to Disclose
 
Jan Drappatz
Leadership - Elsevier
Stock and Other Ownership Interests - Biogen; Bristol-Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Pfizer
Honoraria - Agios; Elsevier; Novocure; UpToDate
Consulting or Advisory Role - Agios; Immunomic Therapeutics; Novocure; Oncorus
Patents, Royalties, Other Intellectual Property - uptodate
 
Frances A. Collichio
Research Funding - Amgen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); REPLIMUNE (Inst)
Other Relationship - ACGME
 
Vinay K. Puduvalli
Stock and Other Ownership Interests - Amarin Corporation; Gilead Sciences
Honoraria - Novocure; Orbus Therapeutics; SERVIER
Consulting or Advisory Role - Newave Pharmaceutical (I); NewBio; Novocure; Orbus Therapeutics; SERVIER
Research Funding - BeiGene; Bexion; InSightec; Karyopharm Therapeutics; Kazia Therapeutics; Merck; Radiomedix; Samus Therapeutics; SERVIER
 
Frank S. Lieberman
Research Funding - Imvax (Inst); Inovio Pharmaceuticals (Inst); Novocure (Inst)
 
Javier Gonzalez
Employment - AstraZeneca/MedImmune
 
Pierre Giglio
Stock and Other Ownership Interests - Vanguard Funds
Research Funding - BioMimetix; Denovo Biopharma; Institut de Recherches Internationales Servier; Novocure; Prelude Therapeutics
 
Xun Bao
No Relationships to Disclose
 
S. Percy Ivy
No Relationships to Disclose
 
Ranjit Bindra
Leadership - Athena Therapeutics; Cybrexa Therapeutics
Stock and Other Ownership Interests - Athena Therapeutics; Cybrexa Therapeutics
Consulting or Advisory Role - AstraZeneca/MedImmune; Cybrexa Therapeutics; Novocure; Prelude Therapeutics; Prelude Therapeutics; Syros Pharmaceuticals; Third Bridge
Research Funding - Athena Therapeutics; Cybrexa Therapeutics
Patents, Royalties, Other Intellectual Property - Patent filed on on PPM1D as a biomarker NAMPTi sensitivity Patent filed on use of IDH1/2 as a biomarker for PARPi sensitivity
 
Antonio Marcilio Padula Omuro
Consulting or Advisory Role - BTG; KIYATEC; Merck; Ono Pharmaceutical
Research Funding - Arcus Biosciences (Inst)
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Relay Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech